Select News

Jul 7 2015

Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial

Jul 7 2015

CHAPEL HILL, N.C., July 7, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP). Top-line efficacy and safety data from this study are expected to be announced by the end of the year.

READ MORE

Jul 7 2015

Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC - 1002

Jul 7 2015

ANN ARBOR, MI — (Marketwired) — 07/07/15 — Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the 240 mg partial clinical hold on ETC-1002 (bempedoic acid). This action by FDA will now allow ETC-1002 to be used at doses above 240 mg in clinical studies. Esperion plans to initiate the Phase 3 clinical program for ETC-1002 in the fourth quarter of this year using the already optimized 180 mg dose.

READ MORE

Jul 1 2015

Advion Acquired by Bejing Bohui Innovation Technology, Inc.

Jul 1 2015

July 1, 2015 – Ithaca, NY – As previously mentioned in the June 5, 2015 announcement of the signing of the Merger Agreement, effective July 1, 2015, Beijing Bohui Innovation Technology, Ltd. completed the acquisition of Advion, Inc.

READ MORE

Jun 25 2015

Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement Disorders

Jun 25 2015

APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson’s Disease

TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company”) today announced that it presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of OFF episodes associated with Parkinson’s disease (PD). Data from the Company’s CTH-105, CTH-104 and CTH-103 clinical studies, presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) in San Diego, California, showed APL-130277 significantly improved PD symptoms (as measured by MDS-UPDRS Part III), rapidly turned patients from the OFF to ON state and was generally safe and well tolerated.

READ MORE

Jun 19 2015

Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101

Jun 19 2015

FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results

BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to AR101, the company’s lead investigational product, for oral immunotherapy of peanut-allergic children and adolescents 4-17 years of age.

READ MORE

Jun 18 2015

Cynapsus Therapeutics Inc. Announces Pricing of US$63.0 Million Public Offering of Common Shares in the United States

Jun 18 2015

TORONTO, ONTARIO — Cynapsus Therapeutics Inc. (TSX:CTH)(OTCQX:CYNAD) (the “Company” or “Cynapsus”) announced today the pricing of its underwritten public offering in the United States of 4,500,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of approximately US$63.0 million. In connection with the offering, the Company has granted to the underwriters a 30-day option to purchase up to an additional 675,000 common shares at the public offering price, less the underwriting discount. The offering is expected to close on or about June 23, 2015, subject to customary closing conditions. The Company’s common shares are currently, and will continue to be, listed on the Toronto Stock Exchange (“TSX”) under the symbol “CTH,” and trading of the common shares is expected to commence on the NASDAQ Global Market (“NASDAQ”) under the symbol “CYNA” on June 18, 2015.

READ MORE

Jun 17 2015

Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)

Jun 17 2015

NEW YORK– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic constipation (CIC).

READ MORE

Jun 5 2015

Beijing Bohui Innovation Technology Co., Ltd. (Bohui) Agrees to Acquire Advion, Inc.

Jun 5 2015

June 5, 2015 – Ithaca, NY – Advion, Inc., a leading systems and consumables developer for the life sciences industry, announces it has signed a definitive agreement to be acquired by Bohui with an expected close date on June 30, 2015. The acquisition is strategic for both companies and will enable Advion to broaden its investments in the areas of life science, clinical, and food safety applications. Advion will continue to trade under its current name and brand, with all employees and executives remaining with the company. All three (3) operations and locations in Ithaca, NY are expected to remain unchanged into the future.

READ MORE

Apr 20 2015

Spirox, Inc. Announces Closing of $18.5MM Series B Financing

Apr 20 2015

MENLO PARK, Calif., April 20, 2015 /PRNewswire/ — Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round. Spirox, which is developing a novel, minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat patients with nasal obstruction, intends to use the funding to complete development, seek US marketing authorization, and initiate product commercialization.

READ MORE

Apr 16 2015

TransEnterix Announces Completion of GLP Studies

Apr 16 2015

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of its GLP Studies using the SurgiBot system, its patient-side robotic surgery system. Management also commented that the Company remains on track to submit its FDA 510(k) filing in mid-2015.

READ MORE